Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

Basit Öğe Kaydı
dc.authorid0000-0003-3168-2510
dc.authorid0000-0002-9017-763X
dc.authorid0000-0002-8674-4873
dc.contributor.authorÇorum, Orhan
dc.contributor.authorYıldız, Ramazan
dc.contributor.authorİder, Merve
dc.contributor.authorAltan, Feray
dc.contributor.authorOk, Mahmut
dc.contributor.authorÜney, Kamil
dc.date.accessioned2020-03-26T20:19:07Z
dc.date.available2020-03-26T20:19:07Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümüen_US
dc.description.abstractThe aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high-performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half-life (t(1/2 lambda z)) 1.85 and 3.31 hr, area under the plasma concentration-time curve (AUC(0-infinity)) 15.74 and 174 hr * mu g/ml, volume of distribution at steady-state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr(-1) kg(-1), respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 mu g/ml, time to reach peak concentration 1 and 1.5 hr, t(1/2 lambda z) 4.74 and 3.62 hr, and AUC(0-infinity) 22.75 and 147 hr * mu g/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12-hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of <= 0.5 and <= 4 mu g/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.en_US
dc.identifier.citationCorum, O., Yildiz, R., Ider, M., Altan, F., Ok, M., Uney, K. (2019). Pharmacokinetics and Bioavailability of Cefquinome and Ceftriaxone in Premature Calves. Journal of Veterinary Pharmacology and Therapeutics, 42(6), 632-639.
dc.identifier.doi10.1111/jvp.12789en_US
dc.identifier.endpage639en_US
dc.identifier.issn0140-7783en_US
dc.identifier.issn1365-2885en_US
dc.identifier.issue6en_US
dc.identifier.pmid31197850en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage632en_US
dc.identifier.urihttps://dx.doi.org/10.1111/jvp.12789
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38078
dc.identifier.volume42en_US
dc.identifier.wosWOS:000501034000008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUney, Kamil.
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectbioavailabilityen_US
dc.subjectcefquinomeen_US
dc.subjectceftriaxoneen_US
dc.subjectpharmacokineticsen_US
dc.subjectpremature calvesen_US
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calvesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Orhan CORUM.pdf
Boyut:
524.22 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Klinik Öncesi Bilimler/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu